Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 17 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Other				06-2247 NCT00442533


2.		A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 120				Pharmaceutical / Industry				A6181111 NCT00428597


3.		Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				CRAD001C2324 NCT00510068

Last Modified: 8/1/2008 First Published: 9/23/2005


4.		Phase I/II Pilot Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin (FOLFOX) With Bevacizumab in Patients With Advanced Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				UCSF-04458 NCT00227617


5.		RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				07-325 NCT00576680


6.		Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				END0002 97273, END0002, NCT00398320, NCT00398320

Last Modified: 10/26/2007 First Published: 3/22/2007


7.		Phase II Study of Pazopanib Hydrochloride in Patients With Low- or Intermediate-Grade Advanced Neuroendocrine Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and over				NCI				MDA-2006-0077 MDACC 2006-0077, 7650, NCT00454363


8.		Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				MCC-14888 NCT00434109


9.		TheraSphere for the Treatment of Liver Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				G040148 NCT00511862


10.		Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				PTK787/ZK222584 LSU IRB-6355, NCT00590343

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute